Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Are Coated Devices the Future of Interventional Therapeutics?

Greystone Associates
Posted on: 03 Nov 04

New Survey by Greystone Associates Examines Potential for Drug-Coated Devices

(Amherst, NH) – Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices (e.g., coronary stents) provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes.

Ongoing improvements in specialty coating platforms are expanding the number of active compounds are can be formulated as drug-device combination products.  “We expect the clinical results from the current generation of coated device designs to yield valuable insight that will accelerate technology improvements, resulting in coating formulations that can be further tailored to specific therapeutic targets,” explains George Perros, Greystone Managing Director.

The potential impact is far-reaching. The number of conditions requiring interventional therapeutics that can potentially benefit from drug eluting combination devices is significant. “The early success of drug eluting devices such as the CypherÔ stent is resulting in increased interest in coated device combination delivery systems for a host of conditions, based on a growing list of substrates,” adds Perros.

These survey findings are contained in a new and comprehensive report: Drug Delivery Coatings: Devices, Therapies and Emerging Opportunities. The report contains a comprehensive assessment of drug eluting coating technology, and provides an assessment of current and probably future coated drug-device combination products, profiles of market participants, industry data and forecasts, and detailed analysis of regulatory and market factors. Organized and written to be of maximum value to pharmaceutical professionals, device developers, drug delivery market participants, and coating technology providers, the report provides a detailed analysis of the growing potential for coating-enabled drug eluting devices in interventional therapeutics.

More information is available at www.greystoneassociates.org .

 

 About Greystone

 

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

 

Contact:

 

Mark Smith

Voice: 603-595-4340

Fax: 603-804-0466

marksmith@greystoneassociates.org

www.greystoneassociates.org                                         Source: Greystone Associates

 

For more information:
http://www.greystoneassociates.org/Drug_Delivery_Coatings.htm

Editor's Details

Mark Smith
Greystone Associates
http://www.greystoneassociates.org
603-595-4340
marksmith@greystoneassociates.org

Last updated on: 27/08/2010

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.